FIGURE 1 from Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer

• DOI: 10.1158/2767-9764.24496199
• Publication Date: 2023-11-03T14:43:43Z
• Authors: Ruiliang Wang; Qiufan Xu; Hanxu Guo; Guanjie Yang; Jun Zhang; Hong Wang; Tianyuan Xu; Changcheng Guo; Jing Yuan; Yanyan He; Xiaoying Zhang; Hongliang Fu; Guang Xu; Binghui Zhao; Jun Xie; Tingting Zhao; Longfei Huang; Jiansheng Zhang; Bo Peng; Xudong Yao; Bin Yang

<p>Study design and integrative landscape of SMs, CNVs, and deleterious GMs in patients with AVPC. <b>A,</b> Flow diagram of patients according to treatment history. Tumor tissue and matched ctDNA from 63 patients with clinically defined AVPC. All of them underwent systemic treatment. Among them, 14 patients received local treatment, while 59 patients did not. The systemic treatment methods included NHT (enzalutamide, abiraterone, and apalutamine), Chemotherapy (additional platinum-based chemotherapy or docetaxel only), and other therapies (inhibitors of tyrosine kinases, PD-1 or PARP inhibitor). <b>B,</b> Landscape of alterations involving 30 selected genes in progressive tumor tissues and matched ctDNA from patients with AVPC. <b>C,</b> Landscape of alterations involving signaling pathways in progressive tumor tissues and matched ctDNA from patients with AVPC. Significance was determined using <i>χ</i>² and Fisher exact tests. ***, <i>P</i> < 0.001.</p>